戻る Agenda
Session 4B: Medical Errors Due to Product Design and Development
Session Chair(s)
Diana Van Riet-Nales, PharmD, PhD
Senior Assessor; Member of EMA Quality Working Party
Medicines Evaluation Board (MEB), Netherlands
Medication errors may result in patient harm or death. Risk is known to increase when the product design is insufficiently tailored to patient needs e.g. children, (older) patients. Demographic changes strengthen the importance to identify and mitigate risk in science, regulation and drug development.
Speaker(s)
Medication Safety in the Hospital – Challenges and Hurdles
Martin Hug, PhD
University Medical Center Freiburg, Germany
Professor, Chief Pharmacist
Considering the Human Factor When Mitigating Risks of Medication Errors - an Industry Perspective
Isabel Menz, MSc
Medical Human Factors GmbH, Germany
Managing Director Germany
Medication Errors: How the Drug Design May Mitigate Risk - a Regulatory Perspective
Diana Van Riet-Nales, PharmD, PhD
Medicines Evaluation Board (MEB), Netherlands
Senior Assessor; Member of EMA Quality Working Party
Panel Discussion
Sven Stegemann, PhD
Graz University of Technology; Capsugel, Austria
Professor of Patient Centric Drug Design and Manufacturing